The European Commission has granted marketing authorization for Rylaze for use as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia and lymphoblastic lymphoma in adult and pediatric patients 1 month and older who developed hypersensitivity or silent inactivation to E. coli–derived asparaginase.
DUBLIN, Sept. 21, 2023 /PRNewswire/ Jazz Pharmaceuticals plc today announced that the European Commission has granted marketing authorization for Enrylaze® for use as a component of a.
Jazz Pharmaceuticals (JAZZ) Granted EU Approval for Enrylaze streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.